Literature DB >> 28864202

Pathogenesis of thromboangiitis obliterans: Gene polymorphism and immunoregulation of human vascular endothelial cells.

Xiao-Lei Sun1, Betty Yuen-Kwan Law2, Ivo Ricardo de Seabra Rodrigues Dias2, Simon Wing Fai Mok2, Yan-Zheng He3, Vincent Kam-Wai Wong4.   

Abstract

Thromboangiitis obliterans (TAO) is a nonatherosclerotic, segmental, inflammatory vasculitis, which commonly affects the small- and medium-sized arteries of the upper and lower extremities. Despite its discovery more than a century ago, little progress has been made in its treatment. Unless the pathogenesis is elucidated, therapeutic approaches will be limited. The purpose of this review article is to collate current knowledge of mechanisms for the pathogenesis of thromboangiitis obliterans and to propose potential mechanisms from a genetic and immunoreactive point of view for its inception. Therefore, we discuss the possibility that the pathogenesis of this disease is due to a type of gene polymorphism, which leads to an immunological inflammatory vasculitis associated with tobacco abuse, highly linked to T cells, human vascular endothelial cells (HVECs), and the TLR-MyD88-NFκB pathway, distinct from arteriosclerosis obliterans and other vasculitides.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Buerger's disease; IL-33; MyD88; Polymorphism; Thromboangiitis obliterans; Type 2 helper T cells

Mesh:

Year:  2017        PMID: 28864202     DOI: 10.1016/j.atherosclerosis.2017.08.009

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  7 in total

1.  The IL-33/sST2 Axis in Thromboangiitis Obliterans.

Authors:  Hiva Sharebiani; Mehran Mohareri; Ali Mirhosseini; Bahare Fazeli
Journal:  J Inflamm Res       Date:  2020-07-16

2.  Sequential intravenous allogeneic mesenchymal stromal cells as a potential treatment for thromboangiitis obliterans (Buerger's disease).

Authors:  Jorge D Martin-Rufino; Francisco S Lozano; Alba M Redondo; Eva M Villaron; Raquel Rueda; Rafael Fernandez-Samos; Fermin Sanchez-Guijo
Journal:  Stem Cell Res Ther       Date:  2018-05-30       Impact factor: 6.832

3.  Levistilide A Ameliorates NLRP3 Expression Involving the Syk-p38/JNK Pathway and Peripheral Obliterans in Rats.

Authors:  Huining Guo; Li Sun; Shuang Ling; Jin-Wen Xu
Journal:  Mediators Inflamm       Date:  2018-08-12       Impact factor: 4.711

4.  Integration of traditional Chinese medicine and nibble debridement and dressing method reduces thrombosis and inflammatory response in the treatment of thromboangiitis obliterans.

Authors:  Jianhua Li; Jingfeng Zhong; Chunfa Huang; Jiewen Guo; Bingyu Wang
Journal:  Ann Transl Med       Date:  2021-09

5.  Cilostazol on the expression of ICAM-1, VCAM-1 and inflammatory factors in plasma in patients with thromboangiitis obliterans.

Authors:  Fuchen Song; Bo Ji; Ting Chen
Journal:  Exp Ther Med       Date:  2018-07-11       Impact factor: 2.447

Review 6.  Delicate Role of PD-L1/PD-1 Axis in Blood Vessel Inflammatory Diseases: Current Insight and Future Significance.

Authors:  Priya Veluswamy; Max Wacker; Maximilian Scherner; Jens Wippermann
Journal:  Int J Mol Sci       Date:  2020-10-31       Impact factor: 5.923

7.  Thromboangiitis obliterans plasma-derived exosomal miR-223-5p inhibits cell viability and promotes cell apoptosis of human vascular smooth muscle cells by targeting VCAM1.

Authors:  Ying Deng; Jindong Tong; Weijun Shi; Zhongyi Tian; Bo Yu; Jingdong Tang
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.